Name: 2nd Annual MarketsandMarkets Cell-Gene therapy Bioprocessing Online Conference( Time Zone - EASTERN STANDARD TIME (EST)
Start: 2020-06-25
End: 2020-06-26

WHAT TO EXPECT

Bioprocessing of 3D cell culture
CHO cell lines bioprocessing
Automation of cellular therapies
AAV vector production
Process development and monitoring of cell-gene therapies
Optimization of cell-gene therapies
Supply chain and reimbursement issues
Regulatory guidelines cell and gene-based medicines

Learn the latest advancement and opportunities in the area of manufacturing of cell-gene therapies
Gain insights in the area of the automated and most effective manufacturing processes
Network with the key professionals addressing the strategies of supply chain and regulatory hurdles

From Therapeutics and Pharmaceuticals, Cell & Gene therapy-based companies:

Engineers/ Scientists/ Researchers/ Project leaders in:

Bioprocess development
Process development
GMP/Manufacturing
Cellular Therapy
Gene Therapy
Quality Control
Cell Engineering
Regulatory affairs

CONFERENCE AGENDA

Opening remarks by Chairperson Tiffany Rau, Global Leader in Process Development (R &D, CMC), Manufacturing, & Commercialization-, Biotechnology, Biopharmaceuticals	08:55 - 09:00
CELL THERAPY BIOPROCESSING AND DEVELOPMENT
Accelerating process and product development using DoE and predictive modelling Tiffany Rau, Global Leader in Process Development (R &D, CMC), Manufacturing, & Commercialization-, Biotechnology, Biopharmaceuticals	09:00 - 09:35
Next-generation immunogene therapies: Precision manufacturing for enhanced impact Jan Joseph Melenhorst, Adjunct Associate Professor, Upenn	09:35 - 10:10
The use of capillary electrophoresis in gene therapy product testing Steve Lock, Marketing & Marketing Development Manager , SCIEX	10:10 - 10:40
Translating Tissue Engineered Medical Product from laboratory to clinic Sarindr Bhumiratana , Chief Scientific Officer , Epibone	10:40 - 11:10
Simple and effective methods for purification and determination of molecular weight of DMT-on and DMT-off oligonucleotides Bill Evans, Process Chromatography Technical Specialist , Tosoh Bioscience LLC	11:10 - 11:40
One on One Networking	11:40 - 11:50
Effectively securing cell and gene therapies with closed systems Jayanthi Grebin, Senior Business Development Manager, Cell & Gene Therapy , CPC	11:50 - 12:10
Cytokines and growth factors: Why should you give a HEK Fiona Bellot, Protein Sales Manager, Proteintech	12:10 - 12:30
PROCESS MONITORING & QUALITY CONTROL
Process development of antigen-specific T cells Patrick J. Hanley, Director of GMP for Immunotherapy, The Children’s Research Institute	12:30 - 13:05
Magic on ice: Next generation DMSO-free biopreservation for cell manufacturing and processing Xiaoxi Wei, Founder & CEO, X-Therma Inc.	13:05 - 13:40
Manufacturing Stem Cell derived products and solving the immune issue Mahendra Rao, Chief Executive Officer, panCella	13:40 - 14:15
One on One Meeting & Networking	14:15 - 15:00
End of Day 1	15:00 - 15:00

Opening remarks by Chairperson Janet Rothberg, Development Manager, CCRM	09:15 - 09:20
Importance of identifying critical materials Dominic Clarke, Global Head Cell Therapy, Strategy and Innovation, , Charles River Laboratories	09:20 - 09:55
Panel Discussion: Autologous vs Allogenic	09:55 - 10:30
Control Potential viral contaminants in biologics with effective testing Margaret Temple, Business Development Manager, SGS	10:30 - 11:00
Scalable lentiviral vector manufacture - The transition from transient to stable systems Gavin Allsop, Senior Business Development Manager, OXGENE	11:00 - 11:30
Upstream Process Development in stem cell manufacturing Janet Rothberg, Development Manager, CCRM	11:30 - 12:05
One on One Networking	12:05 - 12:15
Process development and monitoring of cell-gene therapies Don Healey, SVP Operations and Site Head, KBI Pharma	12:15 - 12:50
LOGISTICS, REGULATORY & INVESTMENT
Building a leading-edge supply chain, while maintaining flexibility Devyn Smith, Chief Executive Officer, Arbor Biotechnologies	12:50 - 13:20
FDA guidelines for regulatory issues involved cell therapy manufacturing Scott Burger, Principal, Advanced Cell & Gene Therapy LLC	13:20 - 13:55
Determinants of durable response upon treatment with Axi-Cel John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences	13:55 - 14:30
End of Conference	14:30 - 14:30